Technology Listings


Cross-Reactive Antibodies Against Influenza Virus

Application

Human recombinant antibodies against influenza, including H1N1, for the development of diagnostic tests and universal flu vaccines.

Key Benefits

Broadly protective antibodies against multiple influenza strains

Market Summary

Influenza spreads swiftly and globally, causing some of the most severe pandemics in the last century. Each year, a few million people are afflicted with a severe influenza infection; however, these numbers can rise during pandemic years. During the 1918 H1N1 infection, over 100 million lives were claimed. These waves of infection are a unique characteristic to influenza because of its rapid evolution and ease of transmission. Seasonal vaccines are available to developed countries, but they are deemed obsolete within a year due to quick mutation rate. There is a high public health interest to develop diagnostic tests to identify infections and produce vaccines that will protect against new influenza strains throughout the years.

Technical Summary

Researchers at Emory University developed antibodies against influenza, including strains of H1N1. The majority of neutralizing antibodies available are broadly cross reactive with recent H1N1 strains as well as the highly pathogenic 1918 and avian H1N1. These neutralizing antibodies bound primarily to hemagglutinin (HA), a major glycoprotein found on the surface of an influenza virus. Because these antibodies target a conserved HA region present in many influenza strains, they are an ideal candidates for developing a universal influenza vaccine. In vivo challenge experiments demonstrate that the neutralizing antibodies are able to protect mice exposed to H1N1. These antibodies are promising targets for influenza diagnostic test and vaccine development.

Developmental Stage

In vivo mouse models do not develop influenza when administered neutralizing antibodies prior to infection or even 3 days after infection.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Nationalized PCT - United States United States 13/500,879 9,458,226 10/12/2010 10/4/2016 4/26/2031
Nationalized PCT - Foreign Canada 2,824,389   1/10/2012    
Nationalized PCT - Foreign Australia 2012205663   1/10/2012    
Nationalized PCT - Foreign EP 12734165.9   1/10/2012    
Nationalized PCT - Foreign Australia 2012326025   10/18/2012   10/18/2032
Nationalized PCT - Foreign Canada 2,852,474   10/18/2012   10/18/2032
Nationalized PCT - Foreign EP 12841118.8   10/18/2012   10/18/2032
Nationalized PCT - United States United States 14/350,632 9,321,829 10/18/2012 4/26/2016 10/18/2032
Nationalized PCT - United States United States 13/978,607 9,469,685 7/8/2013 10/18/2016 1/10/2032
Continuation United States 15/083,515 3/29/2016    
Tech ID: NCS.07
Published: 11/3/2013
Category
Diagnostics
Research Tools
Therapeutics

Contact
Justin Burns
Licensing Associate
Emory University
justin.burns@emory.edu

Inventor(s)
Rafi Ahmed
Patrick Wilson
Jens Wrammert

Keywords
Antibody
Microbiology/Infectious Diseases